The targeted delivery of optimized stem cells directly into injured tissues has been used to maximize efficacy and minimize systemic exposure. Still, despite hundreds of clinical trials evaluating mesenchymal stem cell (MSC) therapy as a treatment, clinical efficacy remains highly variable. Investigators at Case Western Reserve University have developed an optimized combination of cytokines and growth factors applied to MSCs (HXB-319).
Research at Humanwell Healthcare (Group) Co. Ltd. has led to the development of heterocyclic 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitors reported to be useful for the treatment of acute lung injury, diabetes, fibrosis, graft-vs.-host disease, heart failure, inflammatory bowel disease, alopecia and osteoporosis, among others.
Cellular mediators like cytokines that are released as a reaction to cell injury or excessive stimulation can lead to the synthesis of chemotactic eicosanoid leukotriene B4 (LTB4) among others. This mediator acts as a potent chemokine promoting migration of macrophages and neutrophils into tissues during inflammation. Researchers from CNRS, Universitat de Barcelona and colleagues reported the synthesis and evaluation of new 1,4-benzodioxine derivatives with selective LTB4 antagonism activity that led to the identification of [I] as the lead compound, which had higher affinity for LTB4 receptor with an IC50 value of 288 nM.
Huchembio Co. Ltd. has described signal transducer and activator of transcription 3 (STAT3) inhibitors reported to be useful for the treatment of autoimmune diseases, atherosclerosis, inflammatory disorders, cancer, diabetic retinopathy, diabetes, osteoporosis and viral infections.
RSS
